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Purpose of review:  
To describe the VISION 2020: The Right to Sight, global initiative for the elimination 
of avoidable blindness, the contribution of glaucoma to the magnitude of global 
blindness and priorities going forward. 
Recent findings: Although the target of the World Health Organization’s Global 
Action Plan (2014-2019) has not been met in terms of 25% reduction in avoidable 
blindness, there is evidence that the contribution of glaucoma to blindness and vision 
impairment is reducing. Yet this focus on a threshold of visual acuity by which to 
measure prevalence underestimates the true burden of glaucoma. Recent 
population-based studies demonstrate the scale of the unmet need. 
Summary: Scaling up of integrated people-centred eye care, by embedding 
glaucoma detection and care pathways in health systems with a strong focus on 
primary health care, is necessary. Solutions include reinforcing existing pathways 
while emphasising high quality glaucoma care, in addition to novel solutions such as 
self-testing, digital portable technology, artificial intelligence, and multi-level care 
pathways that extend to the most underserved parts of the global community. 
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Introduction: 
VISION 2020: The Right to Sight, the joint global initiative for the elimination of 
avoidable blindness of WHO and the International Agency for the Prevention of 
Blindness, has been important in increasing awareness of avoidable blindness and 
has resulted in the establishment of regional and national entities that facilitate a broad 
range of activities.1 The adoption of resolution WHA66.4 entitled Towards universal 
eye health: a global action plan 2014–2019 by the Sixty-sixth World Health Assembly 
opened up a new opportunity for Member States to progress with their efforts to 
prevent visual impairment and strengthen rehabilitation of the blind in their 
communities. As the period of the World Health Organization’s Global Action Plan 
(2014-2019) comes to an end, there is recognition that its target of a 25% reduction in 
avoidable blindness has not yet been met owing largely to the aging of populations.2  
 
Text of review: 
As countries move up the spectrum of development, more people live into adulthood, 
the average age of the population increases and the disease burden shifts to non-
communicable diseases and disabilities. Glaucoma, a disease with a strong 
association with ageing, is a classic example of the effects of this ‘epidemiological 
transition’.3 The purpose of this review is to identify some of the recent key 
developments in our knowledge of the epidemiology of glaucoma and its relevance for 
the advocacy efforts that VISION 2020 promoted. 
 
One of the metrics for measuring health burden is Years Lived with Disability (YLD). 
In 2018, the Global Burden of Disease Study estimated that in 2017, prevalent 
glaucoma causing blindness or vision impairment accounted for 5.99 million (95% 
uncertainty interval (UI): 5.17.5 to 6.98) YLDs.4 The age-standardised rate had 
decreased significantly by 6.0% (95% UI,−7.4 to −4.2) between 1990 and 2007, and 
by 4.7% (95% UI,−5.8 to −3.6) between 2007 and 2017. These findings from a global 
statistical model involving cross-sectional data from many population-based studies 
confirms the long-term reduction in glaucoma blindness incidence noted by the very 
few studies that have measured this.5 In terms of its overall contribution to blindness, 
a series of regional reports estimate glaucoma’s contribution to blindness in 2015 to 
range between 6% (South Asia) to 16% (Sub-Saharan Africa), while for vision 
impairment (<6/18 to 3/60 presenting visual acuity in the better eye), its contribution 
ranged between 1% (South Asia) to 4% (Sub-Saharan Africa).6-11 It is important to 
note that these models consider only the cases of glaucoma that reduce visual acuity 
below 6/18 in the better eye with no consideration given to severity of visual field loss 
in the definition. Therefore these estimates very much underestimate the full ‘burden’ 
of disability or impact on quality of life caused by glaucoma. 
 
Recent population-based surveys, such as the National Eye Health Survey in 
Australia estimated the actual prevalence of glaucoma (irrespective of visual acuity) 
in non-indigenous participants to be 1.8% in those <60 years, 3.0% in those aged 
60–69 years, 4.2% in those aged 70–79 years and 6.7% in those aged ≥80 years.12 
While in indigenous Australians, the prevalence was lower. Nearly half of non-
Indigenous participants and more than 70% of Indigenous participants with 
glaucoma did not have a known history of the disease. These low rates of detected 
glaucoma are not dissimilar to those reported in the past in other high-income 
countries such as Greece 13 or the USA.14 A recent systematic review also makes 
the important point of how little is known of the prevalence and causes of vision loss 
in the indigenous peoples of the World, most of which is avoidable.15 
 
China must present one of the most rapidly changing populations in terms of 
demographics. A recent analysis from multiple in-country population-based studies 
estimated 13.12 million people (95% CI = 9.88–17.68) to be affected in 2015, with 
more than half (54%) being Primary Angle Closure glaucoma cases. Urbanicity was 
a risk factor after controlling for age and gender. By 2050 the authors estimate 25 
million people in China will be affected by glaucoma.16 Additionally in Singapore 
Chinese, a recent study estimates the number of people affected by glaucoma to 
also double (between 2015 and 2040).17  
 
The setting of targets was only one part of the Vision 2020 initiative. The impact that 
it has had in establishing regional and national entities, often with national Action 
Plans has been very significant and there is no doubt that this has promoted 
increasing awareness of avoidable blindness by both governments and non-
governmental organisations. Most countries now have glaucoma professional 
organizations and super-national bodies such as the World Glaucoma Association 
have been successful in raising the profile of glaucoma.18 Addressing the existing 
burden of glaucoma and implementation of prevention strategies for glaucoma will 
always be more complicated than for example cataract, where most countries have 
increased their cataract surgical rate. However, just as was experienced with the 
early decades of increased cataract surgery, the quality of glaucoma care is just as 
important as quantity. Screening must be cost-effective and sustainable and this may 
be possible in some populations19 yet in most areas of the World there is a reliance 
on opportunistic case detection. Efforts to increase awareness of glaucoma in 
primary care and in existing eyecare programs such as cataract and diabetic 
retinopathy screening need to be heightened. 
 
Modifications in our treatment options for newly diagnosed glaucoma based on 
recently published evidence may have significant ramifications in low and middle 
income countries.20 21 For example in Africa, where there are many barriers to the 
uptake of glaucoma treatment such as availability, accessibility, and affordability of 
treatments,22 as well as the expense of surgical treatment, selective laser 
trabeculoplasty has been shown to be a favorable alternative to medical or surgical 
care, being highly effective and safe in people of African descent.23 24 
 
Linking the detection of glaucoma with other healthcare case detection programs, 
self-testing, digital portable technology,25 artificial intelligence solutions,26 
telemedicine,27 and multi-level care pathways that extend to the most peripheral 
communities, offers the opportunity to reach the substantial proportion of people who 
remain undiagnosed and who are at significant risk of impaired quality of life with or 
without vision impairment.  
 
Conclusion: 
The World Health Organisation published its first World Report on Vision in October 
2019.28 The theme of the report is to support integrated people-centred eye care, 
embedded in health systems and based on strong primary health care, and to scale 
it up widely. This approach is particularly important for glaucoma with the significant 
advances we have seen recently in the detection and treatment of glaucoma in clinic 
populations yet there is a need to address the unmet need at the population level.   
 
 
Bullet point sentences (5) 
1. There is evidence that the contribution of glaucoma to blindness and vision 
impairment is reducing yet the numbers of people with vision loss due to 
glaucoma is increasing due to increasing age of populations. 
2. The focus on visual acuity thresholds used in blindness/vision impairment 
prevention strategies means that the true burden of glaucoma is 
underestimated.  
3. Awareness of glaucoma among the public even in high income countries 
remains low and population-based studies of glaucoma confirm that the 
majority of people with glaucoma remain undiagnosed. 
4. While glaucoma case detection remains largely opportunistic, efforts to 
increase awareness of glaucoma in primary care and in existing eyecare 
programs such as cataract and diabetic retinopathy screening need to be 
heightened. 
5. Novel technologies, such as telemedicine and deep learning, that can be 
applied to the diagnosis and monitoring of patients with glaucoma offer the 
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